BB Biotech's Q3 2026: Gains and Strategic Portfolio Moves

In the third quarter of 2026, BB Biotech's net asset value (NAV) experienced a 5.6% return in CHF, while its share price increased by 6.5%. This growth occurred alongside a 12% rise in the Nasdaq Biotechnology Index (NBI). Despite the index's broader gains, only a select number of constituents, such as Moderna, drove this performance.

BB Biotech's net profit for the quarter was CHF 175 million, a significant decrease from CHF 448 million in the same period last year. However, the company's net profit year-to-date reached CHF 605 million, up from CHF 106 million the previous year.

The quarter was marked by clinical advancements, with three portfolio companies receiving US drug approvals. Additionally, significant mergers and acquisitions resulted in the strategic redeployment of CHF 280 million. The company initiated twelve new positions and exited eight.

BB Biotech continues to leverage its proprietary AI-native operating system for investment decisions, maintaining its focus on long-term potential in innovative drug development.